HIV protease as an inhibitor target for the treatment of AIDS.

[1]  A. Berger,et al.  On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.

[2]  T. Aoyagi,et al.  Pepstatin, a new pepsin inhibitor produced by Actinomycetes. , 1970, The Journal of antibiotics.

[3]  J. Bindra,et al.  2 – Isolation and Structure , 1977 .

[4]  T. L. Blundell,et al.  Structural evidence for gene duplication in the evolution of the acid proteases , 1978, Nature.

[5]  D. Davies,et al.  Three-dimensional structure of the complex of the Rhizopus chinensis carboxyl proteinase and pepstatin at 2.5-A resolution. , 1982, Biochemistry.

[6]  M. James,et al.  Conformational flexibility in the active sites of aspartyl proteinases revealed by a pepstatin fragment binding to penicillopepsin. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Goff,et al.  Mutations in the gag gene of Moloney murine leukemia virus: effects on production of virions and reverse transcriptase , 1984, Journal of virology.

[8]  Tom Blundell,et al.  The active site of aspartic proteinases , 1991, FEBS letters.

[9]  J. Kay,et al.  Aspartic proteinases and their inhibitors. , 1985, Biochemical Society transactions.

[10]  E. Reddy,et al.  HTLV-III gag protein is processed in yeast cells by the virus pol-protease. , 1986, Science.

[11]  William R. Taylor,et al.  A structural model for the retroviral proteases , 1987, Nature.

[12]  T. L. Blundell,et al.  High resolution X-ray analyses of renin inhibitor-aspartic proteinase complexes , 1987, Nature.

[13]  C. Debouck,et al.  Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Nabel,et al.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells , 1987, Nature.

[15]  E. Lillehoj,et al.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors , 1988, Journal of virology.

[16]  S. Kent,et al.  Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease , 1988, Cell.

[17]  V. Turk,et al.  Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Veber,et al.  HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. , 1988, Biochemical and biophysical research communications.

[19]  E. Lillehoj,et al.  Purification and structural characterization of the putative gag-pol protease of human immunodeficiency virus , 1988, Journal of virology.

[20]  P. Darke,et al.  Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus protease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. L. Le Grice,et al.  Processing protease and reverse transcriptase from human immunodeficiency virus type I polyprotein in Escherichia coli , 1988, Journal of virology.

[22]  T. Copeland,et al.  Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne) , 1988, Journal of virology.

[23]  R. Gallo,et al.  Processing of the structural proteins of human immunodeficiency virus type 1 in the presence of monensin and cerulenin. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Hansen,et al.  Partial purification and substrate analysis of bacterially expressed HIV protease by means of monoclonal antibody. , 1988, The EMBO journal.

[25]  E. Wimmer,et al.  Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli , 1988, Journal of virology.

[26]  D. Baltimore,et al.  Standardized and simplified nomenclature for proteins common to all retroviruses , 1988, Journal of virology.

[27]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Varmus,et al.  Characterization of ribosomal frameshifting in HIV-1 gag-pol expression , 1988, Nature.

[29]  P. Štrop,et al.  Synthetic peptides as substrates and inhibitors of human immune deficiency virus-1 protease. , 1988, The Journal of biological chemistry.

[30]  B. Dunn,et al.  Inhibition of the aspartic proteinase from HIV‐2 , 1989, FEBS letters.

[31]  E. Wimmer,et al.  Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Louis,et al.  Substitution mutations of the highly conserved arginine 87 of HIV-1 protease result in loss of proteolytic activity. , 1989, Biochemical and biophysical research communications.

[33]  John P. Overington,et al.  X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes , 1989, Nature.

[34]  C. Debouck,et al.  Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[35]  W. Lovenberg,et al.  HIV-1 protease: mutagenesis of asparagine 88 indicates a domain required for dimer formation. , 1989, European journal of pharmacology.

[36]  C. Debouck,et al.  Peptide substrates and inhibitors of the HIV-1 protease. , 1989, Biochemical and biophysical research communications.

[37]  J. Sodroski,et al.  Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[38]  B. Dunn,et al.  Effective blocking of HIV‐1 proteinase activity by characteristic inhibitors of aspartic proteinases , 1989, FEBS letters.

[39]  C. Debouck,et al.  Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities. , 1989, Archives of biochemistry and biophysics.

[40]  Marianne Manchester,et al.  Complete mutagenesis of the HIV-1 protease , 1989, Nature.

[41]  J. Eberle,et al.  Inhibition of HIV replication in cell culture by the specific aspartic protease inhibitor pepstatin A , 1989, FEBS letters.

[42]  S. L. Le Grice,et al.  Comparison of the human immunodeficiency virus type 1 and 2 proteases by hybrid gene construction and trans-complementation. , 1989, The Journal of biological chemistry.

[43]  C. Debouck,et al.  Characterization and autoprocessing of precursor and mature forms of human immunodeficiency virus type 1 (HIV 1) protease purified from Escherichia coli , 1989, Proteins.

[44]  A Wlodawer,et al.  Molecular modeling of the HIV-1 protease and its substrate binding site. , 1989, Science.

[45]  B. Ho,et al.  Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity , 1989, Journal of virology.

[46]  A. Skalka.  Retroviral proteases: First glimpses at the anatomy of a processing machine , 1989, Cell.

[47]  A Wlodawer,et al.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.

[48]  T. Copeland,et al.  Synthetic non-peptide inhibitors of HIV protease. , 1989, Biochemical and biophysical research communications.

[49]  M. Jaskólski,et al.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.

[50]  Maria Miller,et al.  Crystal structure of a retroviral protease proves relationship to aspartic protease family , 1989, Nature.

[51]  C. Debouck,et al.  Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[52]  T L Blundell,et al.  X-ray studies of aspartic proteinase-statine inhibitor complexes. , 1991, Biochemistry.

[53]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[54]  R. Dixon,et al.  Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease. , 1989, The Journal of biological chemistry.

[55]  R. Shoeman,et al.  Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Elting,et al.  A fluorometric assay for HIV-protease activity using high-performance liquid chromatography. , 1990, Analytical biochemistry.

[57]  S. Gridley,et al.  Effect of two novel inhibitors of the human immunodeficiency virus protease on the maturation of the HIV gag and gag-pol polyproteins. , 1990, Virology.

[58]  Y. Gluzman,et al.  Isolation of mutants of human immunodeficiency virus protease based on the toxicity of the enzyme in Escherichia coli. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[59]  B. Dunn,et al.  Viral proteinases: weakness in strength. , 1990, Biochimica et biophysica acta.

[60]  S. Foundling,et al.  Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Manneberg,et al.  Identification of a human immunodeficiency virus-1 protease cleavage site within the 66,000 Dalton subunit of reverse transcriptase. , 1990, Biochemical and biophysical research communications.

[62]  Synthetic HIV-2 protease cleaves the GAG precursor of HIV-1 with the same specificity as HIV-1 protease. , 1990, Archives of biochemistry and biophysics.

[63]  V. Kostka,et al.  Sub‐site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV‐1 , 1990, FEBS letters.

[64]  Tomi K. Sawyer,et al.  A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. , 1990, Disease markers.

[65]  E. Wimmer,et al.  Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinase , 1990, Journal of virology.

[66]  A. Tomasselli,et al.  Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease. , 1990, Biochemistry.

[67]  D. Grobelny,et al.  Selective phosphinate transition-state analogue inhibitors of the protease of human immunodeficiency virus. , 1990, Biochemical and biophysical research communications.

[68]  C. Vlahos,et al.  Substitutions at the P2' site of gag p17-p24 affect cleavage efficiency by HIV-1 protease. , 1990, Biochemical and biophysical research communications.

[69]  B. Cambou,et al.  HIV-1 Aspartic Proteinase: High-Level Production and Automated Fluorometric Screening Assay of Inhibitors , 1990 .

[70]  M. Jaskólski,et al.  Structure of the aspartic protease from Rous sarcoma retrovirus refined at 2-A resolution. , 1989, Biochemistry.

[71]  R. Dixon,et al.  Characterization of an active single polypeptide form of the human immunodeficiency virus type 1 protease. , 1990, The Journal of biological chemistry.

[72]  S. Vasavanonda,et al.  Structure-based, C2 symmetric inhibitors of HIV protease. , 1990, Journal of medicinal chemistry.

[73]  Brian W. Metcalf,et al.  Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues , 1990, Nature.

[74]  A. Billich,et al.  Purification, assay and kinetic features of HIV-1 proteinase. , 1990, Biological chemistry Hoppe-Seyler.

[75]  A Wlodawer,et al.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[76]  D. Decamp,et al.  Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. , 1990, The Journal of biological chemistry.

[77]  I. Kuntz,et al.  Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[78]  G R Marshall,et al.  Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease. , 1990, Journal of medicinal chemistry.

[79]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[80]  D. Norbeck,et al.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.

[81]  R. Dixon,et al.  Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. , 1991, The Journal of biological chemistry.

[82]  Thomas Schulze,et al.  In vitro inhibition of HIV‐1 proteinase by cerulenin , 1990, FEBS letters.

[83]  B. Moss,et al.  An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[84]  MiniReview: Antiviral Targets Series, Number 1 , 1990 .

[85]  I. Pastan,et al.  Interdomain hydrolysis of a truncated Pseudomonas exotoxin by the human immunodeficiency virus-1 protease. , 1990, The Journal of biological chemistry.

[86]  W. Farmerie,et al.  Sensitive, soluble chromogenic substrates for HIV-1 proteinase. , 1990, The Journal of biological chemistry.

[87]  V. Kostka,et al.  Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases. , 1990, Biochemical and biophysical research communications.

[88]  J S Mills,et al.  Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. , 1991, Antiviral research.

[89]  S. Vasavanonda,et al.  Potent HIV-1 protease inhibitors with antiviral activities in vitro. , 1991, Biochemical and biophysical research communications.

[90]  D. Norbeck,et al.  Chapter 15. HIV Protease Inhibitors , 1991 .

[91]  Comparison of three inhibitor complexes of human immunodeficiency virus protease. , 1991, Advances in experimental medicine and biology.

[92]  T. Holzman,et al.  Inhibitor stabilization of human immunodeficiency virus type-2 proteinase dimer formation. , 1991, The Journal of biological chemistry.

[93]  J. Springer,et al.  Binding of a Reduced-Peptide Inhibitor and a Statine-Containing Inhibitor to the Protease from the Human Immunodeficiency Virus , 1991 .

[94]  K. Hui,et al.  A rational approach in the search for potent inhibitors against HIV proteinase , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[95]  M. Minnich,et al.  Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease. , 1991, Biochemistry.

[96]  A. Billich,et al.  Analysis of subsite preferences of HIV-1 proteinase using MA/CA junction peptides substituted at the P3-P1' positions. , 1991, Archives of biochemistry and biophysics.

[97]  A. Dalgleish,et al.  HIV-1 proteinase is required for synthesis of pro-viral DNA. , 1991, Biochemical and biophysical research communications.

[98]  D. Norbeck,et al.  Synthesis of (2S,5S,4R)-2,5-diamino-3,3-difluoro-1,6-diphenylhydroxyhexane: the core unit of a potent HIV proteinase inhibitor , 1991 .

[99]  Ro-31-8959/003 , 1991 .

[100]  B. Rosenwirth,et al.  Assay Systems for HIV-1 Proteinase and Their Use for Evaluation of Inhibitors , 1991 .

[101]  Ajit Kumar.  Advances in Molecular Biology and Targeted Treatment for AIDS , 1991, GWUMC Department of Biochemistry Annual Spring Symposia.

[102]  T. Copeland,et al.  Comparison of the HIV‐1 and HIV‐2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag‐Pol polyproteins , 1991, FEBS letters.

[103]  W. Schramm,et al.  HIV-1 reproduction is inhibited by peptides derived frm the N- and C-termini of HIV-1 protease. , 1991, Biochemical and biophysical research communications.

[104]  J. Craig,et al.  Effects of a Specific Inhibitor of HIV Proteinase (Ro 31-8959) on Virus Maturation in a Chronically Infected Promonocytic Cell Line (U1) , 1991 .

[105]  A. Kaplan,et al.  Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[106]  S. Vasavanonda,et al.  Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease , 1991, Antimicrobial Agents and Chemotherapy.

[107]  B. Dunn.  Structure and Function of the Aspartic Proteinases , 1991 .

[108]  T. Copeland,et al.  In situ processing of a retroviral nucleocapsid protein by the viral proteinase. , 1991, Protein engineering.

[109]  I. Weber,et al.  Studies on the role of the S4 substrate binding site of HIV proteinases , 1991, FEBS letters.

[110]  Development of methodology for the synthesis of stereochemically pure Phe.psi.[CH2N]Pro linkages in HIV protease inhibitors , 1991 .

[111]  M. Katharine Holloway,et al.  X-Ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2 Symmetry , 1991 .

[112]  M. Deshpande,et al.  Investigating the stereochemistry of binding to HIV-1 protease with inhibitors containing isomers of 4-amino-3-hydroxy-5-phenylpentanoic acid. , 1991, Biochemical and biophysical research communications.

[113]  A. Israël,et al.  Processing of the precursor of NF-κB by the HIV-1 protease during acute infection , 1991, Nature.

[114]  A Wlodawer,et al.  Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. , 1991, Biochemistry.

[115]  J. Louis,et al.  The effect of salt on the Michaelis Menten constant of the HIV‐1 protease correlates with the Hofmeister series , 1991, FEBS letters.

[116]  G. Marshall,et al.  Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes. , 1991, Journal of medicinal chemistry.

[117]  C. Hutchison,et al.  Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. , 1991, The Journal of biological chemistry.

[118]  R. Heinrikson,et al.  Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. , 1991, The Journal of biological chemistry.

[119]  M. Hemling,et al.  Didemnaketals A and B, HIV-1 protease inhibitors from the ascidian Didemnum sp , 1991 .

[120]  S. Carr,et al.  Human immunodeficiency virus-1 protease. 1. Initial velocity studies and kinetic characterization of reaction intermediates by 18O isotope exchange. , 1991, Biochemistry.

[121]  P. Wirsching,et al.  Phosphonamidates and phosphonamidate esters as HIV-1 protease inhibitors , 1991 .

[122]  W. M. Sanders,et al.  Design and synthesis of HIV protease inhibitors. Variations of the carboxy terminus of the HIV protease inhibitor L-682,679. , 1991, Journal of medicinal chemistry.

[123]  A. Kaplan,et al.  The HIV-1 gag precursor is processed via two pathways: implications for cytotoxicity. , 1991, Biomedica biochimica acta.

[124]  R. Poljak,et al.  The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. , 1991, Biochimie.

[125]  A. Wlodawer,et al.  The complexities of AIDS : an assessment of the HIV protease as a therapeutic target , 1991 .

[126]  J. Huff,et al.  HIV protease: a novel chemotherapeutic target for AIDS. , 1991, Journal of medicinal chemistry.

[127]  D. Fairlie,et al.  Inhibition of HIV-1 proteinase by non-peptide carboxylates. , 1991, Biochemical and biophysical research communications.

[128]  C. Cameron,et al.  A range of catalytic efficiencies with avian retroviral protease subunits genetically linked to form single polypeptide chains. , 1991, The Journal of biological chemistry.

[129]  E A Emini,et al.  Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors. , 1991, Journal of medicinal chemistry.

[130]  J. Springer,et al.  Structure and function of retroviral proteases. , 1991, Annual review of biophysics and biophysical chemistry.

[131]  P. Darke,et al.  HIV-1 protease inhibitory activity of L-694,746, a novel metabolite of L-689,502. , 1991, Biochemical and biophysical research communications.

[132]  J. Tang,et al.  Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S. , 1991, The Journal of biological chemistry.

[133]  Y. Kiso,et al.  KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. , 1991, Chemical & pharmaceutical bulletin.

[134]  O. Takahashi,et al.  Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic. , 1991, Chemical & pharmaceutical bulletin.

[135]  W. M. Sanders,et al.  L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. , 1991, Journal of medicinal chemistry.

[136]  T. Meek,et al.  Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. , 1991, Biochemistry.

[137]  A. Tomasselli,et al.  Zinc inhibition of renin and the protease from human immunodeficiency virus type 1. , 1991, Biochemistry.

[138]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[139]  R. Dixon,et al.  Interaction of mutant forms of the HIV-1 protease with substrate and inhibitors. , 1991, Advances in experimental medicine and biology.

[140]  A Wlodawer,et al.  Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. , 1991, Biochemistry.

[141]  I. Weber,et al.  Comparative analysis of the sequences and structures of HIV‐1 and HIV‐2 proteases , 1991, Proteins.

[142]  J. Louis,et al.  Purification of HIV‐1 wild‐type protease and characterization of proteolytically inactive HIV‐1 protease mutants by pepstatin A affinity chromatography , 1991, FEBS letters.

[143]  D. Matthews,et al.  Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. , 1991, Science.

[144]  Substrate analog inhibitors of HIV-1 protease containing phenylnorstatine as a transition state element. , 1991, Biochemical and biophysical research communications.

[145]  A. Tomasselli,et al.  A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. , 1991, The Journal of biological chemistry.

[146]  C. Morrow,et al.  Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production , 1991, Journal of virology.

[147]  H. Kräusslich.  Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[148]  R. Monaghan,et al.  L-696,474, a novel cytochalasin as an inhibitor of HIV-1 protease. I. The producing organism and its fermentation. , 1992, The Journal of antibiotics.

[149]  New hydroxyethylamine HIV protease inhibitors that suppress viral replication. , 1992, Journal of medicinal chemistry.

[150]  D. Fairlie,et al.  Non-peptidic anti-AIDS agents: inhibition of HIV-1 proteinase by disulfonates. , 1992, Biochemical and biophysical research communications.

[151]  H. Kräusslich.  Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation , 1992, Journal of virology.

[152]  M. Minnich,et al.  Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV proteases. , 1992, Biochemistry.

[153]  J. Weinstein,et al.  In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations , 1992, Antimicrobial Agents and Chemotherapy.

[154]  L. Babe,et al.  Synthetic “interface” peptides alter dimeric assembly of the HIV 1 and 2 proteases , 1992, Protein science : a publication of the Protein Society.

[155]  M. Weir,et al.  Penicillin derived C2-symmetric dimers as novel inhibitors of HIV-1 proteinase. , 1992, Journal of medicinal chemistry.

[156]  A. Mukherjee,et al.  A novel transglutaminase-catalyzed posttranslational modification of HIV-1 aspartyl protease. , 1992, Biochemical and biophysical research communications.

[157]  P. Darke,et al.  Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design. , 1992, Journal of Medicinal Chemistry.

[158]  J. Urban,et al.  Reduced‐bond tight‐binding inhibitors of HIV‐1 protease Fine tuning of the enzyme subsite specificity , 1992, FEBS letters.

[159]  B. Stowasser,et al.  C2-symmetric phosphinic acid inhibitors of HIV protease , 1992 .

[160]  Specific inhibition of HIV-1 protease by boronated porphyrins. , 1992, Journal of medicinal chemistry.

[161]  T. Tam,et al.  Intriguing structure-activity relations underlie the potent inhibition of HIV protease by norstatine-based peptides. , 1992, Journal of medicinal chemistry.

[162]  P. Wirsching,et al.  .psi.[PO2-CH2N+], a new amide bond replacement: potent, slow-binding inhibition of the HIV protease , 1992 .

[163]  D. Fairlie,et al.  Inhibition of HIV-1 proteinase by metal ions. , 1992, The International journal of biochemistry.

[164]  L. Arthur,et al.  Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences , 1992, Journal of virology.

[165]  R. Babine,et al.  The use of HIV-1 protease structure in inhibitor design , 1992 .

[166]  P. Darke,et al.  A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity. , 1992, Journal of medicinal chemistry.

[167]  D. Lambert,et al.  Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells , 1992, Antimicrobial Agents and Chemotherapy.

[168]  J. Louis,et al.  Effect of salt on the kinetic parameters of retroviral and mammalian aspartic acid proteases , 1992 .

[169]  P. Hawkins,et al.  Synthesis of stereochemically defined phosphonamidate-containing peptides: Inhibitors for the HIV-1 proteinase , 1992 .

[170]  H Enomoto,et al.  Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine. , 1992, Chemical & pharmaceutical bulletin.

[171]  Martin J. Stoermer,et al.  Flavones are inhibitors of HIV-1 proteinase. , 1992, Biochemical and biophysical research communications.

[172]  Gregory R. Koch,et al.  L-696,474, a novel cytochalasin as an inhibitor of HIV-1 protease. III. Biological activity. , 1992, The Journal of antibiotics.

[173]  R. Seetharam,et al.  Human immunodeficiency virus type 1 and type 2 protease monomers are functionally interchangeable in the dimeric enzymes , 1992, Journal of virology.

[174]  O. Hensens,et al.  L-696,474, a novel cytochalasin as an inhibitor of HIV-1 protease. II. Isolation and structure. , 1992, The Journal of antibiotics.

[175]  B. Stowasser,et al.  New hybrid transition state analog inhibitors of HIV protease with peripheric C2-symmetry , 1992 .

[176]  Narmada Thanki,et al.  Crystal structure of a complex of HIV‐1 protease with a dihydroxyethylene‐containing inhibitor: Comparisons with molecular modeling , 1992, Protein science : a publication of the Protein Society.

[177]  C. Debouck,et al.  Proteolysis of an active site peptide of lactate dehydrogenase by human immunodeficiency virus type 1 protease. , 1992, Biochemistry.

[178]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[179]  S. Hughes,et al.  Human immunodeficiency virus type 1 gag-protease fusion proteins are enzymatically active , 1992, Journal of virology.

[180]  J. Hartsuck,et al.  pH dependence of kinetic parameters of pepsin, rhizopuspepsin, and their active-site hydrogen bond mutants. , 1992, The Journal of biological chemistry.

[181]  H. Jacobsen,et al.  Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease , 1992, Journal of virology.

[182]  J. Louis,et al.  Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. , 1992, Biochemistry.

[183]  J. Chermann,et al.  Statine based tripeptides as potent inhibitors of HIV-1 replication. , 1992, Biochemical and biophysical research communications.

[184]  C. Morrow,et al.  The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles , 1992, Journal of virology.

[185]  S. Tyagi.  Inhibitors of human immunodeficiency virus-1 protease. , 1992, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[186]  P. Darke,et al.  HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity. , 1992, Journal of medicinal chemistry.

[187]  A M Hassell,et al.  Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. , 1992, Biochemistry.

[188]  J. Westley,et al.  Brominated polyacetylenic acids from the marine sponge Xestospongia muta: inhibitors of HIV protease. , 1992, Journal of natural products.

[189]  C. Debouck,et al.  The HIV-1 protease as a therapeutic target for AIDS. , 1992, AIDS research and human retroviruses.

[190]  J. Robinson,et al.  PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains. , 1992, Virology.

[191]  L. Kuo,et al.  Activity and dimerization of human immunodeficiency virus protease as a function of solvent composition and enzyme concentration. , 1992, The Journal of biological chemistry.

[192]  B. Moss,et al.  HIV-1 protease cleaves actin during acute infection of human T-lymphocytes. , 1992, AIDS research and human retroviruses.

[193]  A. Wlodawer,et al.  Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites. , 1992, Biochemistry.

[194]  K. Ingold,et al.  Two-step binding mechanism for HIV protease inhibitors. , 1992, Biochemistry.

[195]  J. Chermann,et al.  HIV-1 protease inhibitors containing statine: inhibitory potency and antiviral activity. , 1992, Biochemical and biophysical research communications.

[196]  P. Kuzmič.  Kinetic assay for HIV proteinase subunit dissociation. , 1993, Biochemical and biophysical research communications.

[197]  R A Mueller,et al.  Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere. , 1993, Journal of medicinal chemistry.

[198]  L. Kuo,et al.  Dissociation and association of the HIV-1 protease dimer subunits: equilibria and rates. , 1994, Biochemistry.

[199]  K. Murthy,et al.  The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations. , 1994 .